AstraZeneca and Merck asserted the approval of LYNPARZA tablets for patients with Ovarian Cancer

AstraZeneca and Merck asserted the sanctioning of LYNPARZA tablets for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy as approved by the Japanese Ministry of Health, Labour and Welfare. In SOLO-2, the most common adverse drug reactions (≥20%) of any grade reported in patients in the LYNPARZA arm were nausea (66.7%), anemia (39.0%), fatigue (29.7%), vomiting (25.6%), asthenia (24.1%) and dysgeusia (23.1%). In Study 19, the most common adverse drug reactions (≥20%) of any grade reported in patients in the LYNPARZA arm were nausea (64.0%), fatigue (43.4%) and vomiting (21.3%).

Dave Fredrickson, executive vice president, head of the oncology business unit at AstraZeneca, claimed, “We are proud to bring this important first-in-class treatment to women with platinum-sensitive relapsed ovarian cancer in Japan who currently have very few treatment options. The trials show that with LYNPARZA maintenance therapy, women with ovarian cancer can live longer without their disease worsening and LYNPARZA is well tolerated.”